Apolipoprotein ε4 advances appearance of psychosis in patients with Parkinson's disease

Acta Neurologica Scandinavica

Volumn 113, Issue 1, 2006, Pages 14-17

  Feldman, B ^a   Chapman, J ^b,c   Korczyn, A D ^a,b  

^a Be'er Yakov Mental Health Center   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

Apolipoprotein E; Dementia; Neurodegeneration; Parkinson's disease; Psychosis

Indexed keywords

APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; APOLIPOPROTEIN E;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DEMENTIA; DISEASE DURATION; FEMALE; GENE AMPLIFICATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HALLUCINATION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; ONSET AGE; PARANOIA; PARKINSON DISEASE; PARKINSONISM; PERCEPTION DISORDER; PSYCHOSIS; RESTRICTION MAPPING; SYMPTOMATOLOGY; GENETICS; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

AGE OF ONSET; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PROPORTIONAL HAZARDS MODELS; PSYCHOTIC DISORDERS; RISK FACTORS;

EID: 33645234856     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2005.00535.x     Document Type: Article

References (14)

1. K orczyn AD Hallucinations in Parkinson's disease Lancet 2001 358 1031 2
2. G iladi N T reves TA P aleacu D et al. Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease J Neural Transm 2000 107 59 71
3. G iladi N S habtai H B enbunan B et al. The effect of treatment with rivastigmin (Exelon) on cognitive functions of patients with dementia and Parkinson's disease Acta Neurol Scand 2003 in press
4. C hapman J K orczyn AD K arussis DM M ichaelson DM The effects of APOE genotype on age at onset and progression of neurodegenerative diseases Neurology 2001 57 1482 5
5. H arhangi BS de R ijk NC V an D uijn CM V an B roeckhoven C H ofman A B reteler MMB APOE and the risk of PD with or without dementia in a population based study Neurology 2000 54 1272 6
6. Z areparsi S C amicioli R S exton G et al. Age at onset of Parkinson disease and Apolipoprotein E genotypes Am J Med Genetics 2002 107 156 61
7. L i Y-J S cott WK H edges DJ et al. Age at onset in two common neurodegenerative diseases is genetically controlled Am J Hum Genet 2002 70 985 93
8. I nzelberg R C hapman J T reves TA et al. Apolipoprotein E4 in Parkinson disease and dementia: new data and meta-analysis of published studies Alzheimer Dis Assoc Disord 1998 12 45 8
9. K aiser R H ofer A G rapengiesser A et al. l -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism Neurology 2003 60 1750 5
10. F uente -F ernandez R N unez A L opez E The Apolipoprotein E ε4 allele increases the risk of drug-induced hallucinations in Parkinson's disease Clin Neuropharmacol 1999 22 226 30
11. G oetz CG B urke PF L eurgans S et al. Genetic variation analysis in Parkinson disease patients with and without hallucinations Arch Neurol 2001 58 209 13
12. H ilkevich O C hapman J B one BS K orczyn AD Prevalence of APOE ε4 allele in Israeli ethnic groups Harefuah 1999 136 845 7
13. M c K eith IG B urn DJ B allard CG et al. Dementia with Lewy bodies Semin Clin Neuropsychiatry 2003 8 46 57
14. H arrington CR L ouwagie J R ossau R et al. Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types Am J Pathol 1994 145 1472 84